secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021717
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals receives FDA approval for generic Requip XL (ropinirole ER) tablets
--------------------------------------------------------------------------------

- FDA approved ANDA for generic Requip XL (Ropinirole Extended-Release Tablets USP) in 2,4,6,8,12 mg strengths.
- Product indicated for Parkinson's disease; will be marketed under Elite Laboratories label.
- IQVIA data: U.S. branded & generic sales of $10M for 12 months ending September 2025.
- Approval enables Elite to compete in the ropinirole ER tablet market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315225021717/0001493152-25-021717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315225021717/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer